Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Revolo Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : CordenPharma will Provide manufacturing support for Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, for its upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.
Product Name : ‘1104
Product Type : Peptide
Upfront Cash : Undisclosed
April 15, 2021
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Revolo Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement